相关实验视频
Updated: Jun 14, 2025
08:50
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
16.2K
微血管内皮基尔2.1通道的损伤有助于人类高血压中内皮功能障碍
Natalia F Do Couto1,2, Ibra Fancher3, Sara T Granados4
1Division of Pulmonary, Critical Care, Allergy and Sleep, College of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States.
American journal of physiology. Heart and circulatory physiology
|August 30, 2024
概括
高血压通过降低人体动脉内向整形的K+ (Kir2.1) 通道活动来损害内皮功能. 这种Kir2.1功能丧失有助于减少流动诱导的血管扩张,恶化血压控制.
科学领域:
- 心血管生理学心血管生理学
- 内皮细胞生物学 内皮细胞生物学
- 离子通道功能的功能
背景情况:
- 高血压与内皮功能障碍有关,部分原因是氧化 (NO) 的生物可用性降低.
- 内皮内向整整的K+ (Kir2.1) 通道对于流动诱导的NO生产和血管扩张至关重要.
研究的目的:
- 研究Kir2.1通道在人类高血压中内皮功能受损中的作用.
- 为了确定减少的Kir2.1活性是否有助于降低高血压患者的流动诱导血管扩张 (FIV).
主要方法:
- 从正常血压和高血压的人体对抗动脉中测量FIV.
- 使用药理阻断 (ML133) 和基因下调 (dnKir2.1) 的Kir2.1通道.
- 评估了急性高压对Kir2.1功能和FIV的影响.
主要成果:
- 与正常血压对照相比,高血压成年人中的FIV显著降低.
- 阻断或降低Kir2.1的调节会使正常血压患者的FIV受损,而不是高血压患者.
- 基尔2.1-依赖的血管扩张与静缩和静缩血压负相关.
- 急性高血压降低了Kir2.1对血管扩张的贡献.
结论:
- 高血压诱导的Kir2.1通道活性抑制是内皮功能障碍的一个关键机制.
- 减少Kir2.1功能有助于高血压患者的FIV受损.
- 这种功能障碍可能会产生恶化的高血压和进一步的血管功能障碍的循环.
相关概念视频
01:18Hypertension and Regulation of Blood Pressure
2.0K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.0K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
510
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
510
01:23Antihypertensive Drugs: Vasodilators
492
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
492
01:25Antihypertensive Drugs: Direct Renin Inhibitors
511
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
511
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
614
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
614